Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis

McGuinness, CF; Black, MA; Dunbier, AK

Author(s): McGuinness, CF; Black, MA; Dunbier, AK;
Details: Publication Year 2023-11-17,Volume 12,Issue #23,Page 21545-21560
Journal Title: Cancer Medicine
Publication Type: Research article
Abstract: BACKGROUND: Genome-wide measures of genetic disruption such as tumour mutation burden (TMB) and mutation signatures are emerging as useful biomarkers to stratify patients for treatment. Clinicians commonly use cancer gene panels for tumour mutation burden estimation, and whole genome sequencing is the gold standard for mutation signature analysis. However, the accuracy and cost associated with these assays limits their utility at scale. METHODS: WGS data from 560 breast cancer patients was used for in silico library simulations to evaluate the accuracy of an FDA approved cancer gene panel as well as restriction enzyme associated DNA sequencing (RADseq) libraries for TMB estimation and mutation signature analysis. We also transfected a mouse mammary cell line with APOBEC enzymes and sequenced resulting clones to evaluate the efficacy of RADseq in an experimental setting. RESULTS: RADseq had improved accuracy of TMB estimation and derivation of mutation profiles when compared to the FDA approved cancer panel. Using simulated immune checkpoint blockade (ICB) trials, we show that inaccurate TMB estimation leads to a reduction in power for deriving an optimal TMB cutoff to stratify patients for immune checkpoint blockade treatment. Additionally, prioritisation of APOBEC hypermutated tumours in these trials optimises TMB cutoff determination for breast cancer. The utility of RADseq in an experimental setting was also demonstrated, based on characterisation of an APOBEC mutation signature in an APOBEC3A transfected mouse cell line. CONCLUSION: In conclusion, our work demonstrates that RADseq has the potential to be used as a cost-effective, accurate solution for TMB estimation and mutation signature analysis by both clinicians and basic researchers.
Keywords: Apobec; RADseq; Tmb; breast; immune checkpoint blockade
Department(s): Laboratory Research
PubMed ID: 37974533
Publisher's Version: https://doi.org/10.1002/cam4.6711
Open Access at Publisher's Site: https://doi.org/10.1002/cam4.6711
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-12-20 05:40:26

Last Modified: 2023-12-20 06:31:07